Design and participant characteristics of a randomized-controlled trial of telemedicine for smoking cessation among rural smokers

Laura Mussulman a, Edward F. Ellerbeck a, A. Paula Cupertino a, Kristopher J. Preacher c, Ryan Spaulding b, Delwyn Catley d, Lisa Sanderson Cox a, Leah Lambart a, Jamie J. Hunt e, Niaman Nazir a, Theresa Shireman a, Kimber P. Richter b,⁎

aDepartment of Preventive Medicine and Public Health, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, United States
bCenter for Telemedicine & Telehealth, University of Kansas Medical Center, 4330 Shawnee Mission Parkway, Fairway, KS 66205, United States
cPeabody College of Education & Human Development, University of Vanderbilt, 230 Appleton Place, Nashville, TN 37203, United States
dDepartment of Psychology, University of Missouri-Kansas City, 5100 Rockhill Road, Kansas City, MO 64110, United States
eDepartment of Nursing, University of Missouri-Kansas City, 5100 Rockhill Road, Kansas City, MO 64110, United States

Abstract

Introduction: In rural America cigarette smoking is prevalent, few cessation services are available, and healthcare providers lack the time and resources to help smokers quit. This paper describes the design and participant characteristics of Connect2Quit (C2Q), a randomized control trial (RCT) that tests the effectiveness and cost-effectiveness of integrated telemedicine counseling delivered by 2-way webcams mounted on desktop computers in participant’s physician office examining rooms (ITM) versus quitline counseling delivered by telephone in participant’s homes (Phone) for helping rural smokers quit.

Methods/design: C2Q was implemented in twenty primary care and safety net clinics. Integrated telemedicine consisted of real-time video counseling, delivered to patients in their primary care physician’s (PCP) office. Phone counseling, was delivered to patients in their homes. All participants received educational materials and guidance in selecting cessation medications.

Results: The 566 participants were predominantly Caucasian (92%); 9% were Latino. Most (65%) earned <200% of Federal Poverty Level. One out of three lacked home internet access, 40% were not comfortable using computers, and only 4% had been seen by a doctor via telemedicine in the past. Hypertension, chronic lung disease, and diabetes were highly prevalent. Participants smoked nearly a pack a day and were highly motivated to quit.

Discussion: C2Q is reaching a rural low-income population, with comorbid chronic diseases, that would benefit greatly from quitting smoking. ITM is a good delivery model, which integrates care by holding counseling sessions in the patient’s PCP office and keeps the primary care team updated on patients’ progress.

Trial registration: Clinical trials registration: NCT00843505

1. Introduction

Cigarette smoking is the leading preventable cause of death in the United States [1]. Although the prevalence of smoking has declined dramatically (from 42% to 21%) over the past 40 years, [2] progress in rural America lags well behind national trends. In
2009, the prevalence of smoking in non-metropolitan areas was 26%—equivalent to the U.S. prevalence of smoking in 1990 [3].

Physicians play an important role in the smoking cessation process, [4] as they see 70% of all smokers each year [5]. However, physicians face many barriers to routinely counseling patients who smoke [6-9]. Only half of smokers, seeing their physicians are asked about their smoking, [10] fewer receive clear advice to quit, and only a small subset receive pharmacotherapy [11].

Toll-free telephone-based tobacco quitlines are effective for smoking cessation and have the potential to reach virtually every U.S. citizen—including rural smokers. Unfortunately, only 1–2% of smokers use them [12,13]. Telemedicine, as delivered by real-time, two-way video counseling, is another promising treatment delivery system. For multiple health behaviors and outcomes, a Cochrane review of telemedicine versus face-to-face patient care found that telemedicine was as effective as face-to-face treatment and achieved high levels of satisfaction among patients and providers [14]. The only large-scale study to date evaluating telemedicine for smoking cessation is a group-based intervention trial from Canada, which achieved equivalent quit rates between groups receiving in-person versus telemedicine-delivered interventions. This study, however, had a number of limitations. Participants were not randomized into groups, quit rates were based on self report, and the intervention did not include cessation medications [15].

The primary aim of the present study, Connect2Quit, was to determine the effectiveness and cost-effectiveness of integrated telemedicine (ITM) compared to traditional telephone counseling (Phone) for smoking cessation. We sought to compare the standard of care for distance-based tobacco dependence treatment—telephone counseling—to a new model for care at a distance that integrates telemedicine counseling into the patient’s PCP office.

Connect2Quit employs rigorous study design features including individual randomization, fidelity monitoring of intervention procedures, and biochemical verification of smoking status. We designed the intervention to be theoretically based, simple, translatable, and sustainable to enhance its potential for widespread adoption and ultimate impact on public health. In this paper, we describe the design, study protocol, and participant baseline characteristics. We examined the characteristics of participants to ascertain how generalizable findings will be to rural smokers.

2. Methods/design

We designed Connect2Quit (C2Q) to optimize use of the two cornerstones of effective tobacco treatment; counseling and pharmacotherapy [16]. We also designed C2Q to be fully integrated into the patients’ PCP office: C2Q counselors delivered all ITM sessions in the PCP office; C2Q counselors scheduled sessions with clinic receptionists, updated the primary care team on patients’ progress, and worked with the rural providers to help patients select and obtain medication prescriptions. Because telemedicine counseling occurred in the PCP office, patients had the opportunity to immediately ask their health care providers for additional advice regarding pharmacotherapy and prescriptions for smoking cessation medication. We integrated telemedicine counseling into physician offices in order to enhance autonomy support from the health care team and to facilitate support for pharmacotherapy utilization. We designed the quitline condition to be as similar as possible to the majority of quitlines available in the U.S., while at the same time delivering the same content and frequency of counseling as our ITM condition. The counseling manual, number of sessions, length of sessions and study logistics were the same for both ITM and Phone conditions. This comparison permits clear-cut evaluation of a practice innovation—telemedicine-delivered counseling, integrated into medical practice (ITM)—versus telephone quitline counseling. We examined whether our ITM innovation can do a better job of delivering effective tobacco treatment (autonomy-supportive counseling and pharmacotherapy), be more effective, and be more cost-effective, than telephone quitlines. The design did not permit us to evaluate the relative impact of a) improving communication between remote counselors and primary care providers or b) enhancing the counseling experience of the video interface. However, our design allowed us to measure if participants felt greater support from their health care providers, which may translate into greater internal motivation to quit. Nevertheless, there is some risk that patients felt external pressure to quit from providers. Measuring both internal and external motivation allowed us to detect whether provider support translates to internal, “autonomous” motivation or external motivation to quit.

2.1. Design overview

Tables 1 and 2 provide overviews of study components and assessments. Connect2Quit employed an individual-randomized design. Patients assigned to Phone received 4 sessions of in-home telephone counseling and educational materials. Patients in ITM received 4 sessions of telemedicine counseling integrated into the patient’s PCP office and educational materials. In addition, all participants received individually-tailored pharmacotherapy guidance to help them select and obtain cessation medications. The counseling approach and content was the same across both conditions. ITM counseling sessions occurred in the healthcare office, in examining rooms equipped with 2-way webcams mounted on desktop computers. Study assessments were conducted at baseline and months 3, 6, and 12. The University of Kansas Medical Center Ethics Committee approved all study procedures.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>ITM and Phone components.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study components</td>
<td>Session 1</td>
</tr>
<tr>
<td><strong>ITM</strong></td>
<td></td>
</tr>
<tr>
<td>Telemedicine counseling</td>
<td>x</td>
</tr>
<tr>
<td>Quit tips</td>
<td>x</td>
</tr>
<tr>
<td>5-Day plan to quit</td>
<td>Completed, updated when patient desires</td>
</tr>
<tr>
<td>Pharmacotherapy guidance</td>
<td>x</td>
</tr>
<tr>
<td><strong>Phone</strong></td>
<td></td>
</tr>
<tr>
<td>Telephone counseling</td>
<td>x</td>
</tr>
<tr>
<td>Quit tips</td>
<td>x</td>
</tr>
<tr>
<td>5-Day plan to quit</td>
<td>Completed, updated when patient desires</td>
</tr>
<tr>
<td>Pharmacotherapy guidance</td>
<td>x</td>
</tr>
</tbody>
</table>
2.2. Site recruitment

The research team assembled an initial list of 29 candidate clinics in Kansas for recruitment into the study. These clinics had to be sited in a rural location as defined by the Health Resources and Services Administration (HRSA) guidelines; in Kansas this included 88 non-metropolitan counties and other regions [17]. Clinics had to have or be willing to obtain high-speed internet; sufficient patient volume (at least 75 patients/week) to support recruitment; an exam room or other private space available for blocks of time throughout the week that was equipped with a phone and high speed internet access. Researchers sent a letter, and then telephoned all 29 practices. Most (22) clinics elected to participate and had computer equipment installed on site. However, 2 withdrew afterwards due to failure to recruit any patients into the study or inability to obtain sufficient internet capability to transmit sessions, which resulted in a final study site total of 20 clinics. The clinics were located in a wide range of counties that touched three of the Kansas four boarders, 50% of the clinics were located in cities with a population of less than 1800, and three were federally-qualified health clinics. Because C2Q staff faxed prescription requests to physicians, physicians had to agree to participate in order for their patients to be included in the trial. A total of 68 physicians opted to participate in the trial. Because our study employed individual random assignment, the internal validity of the trial was not affected. Although we did not have access to patient data among non-participating physician panels, the large number of physicians opting to participate, gave us confidence that our participants were representative.

2.3. Study equipment and site orientation

At each site, a telemedicine technician met with the staff member responsible for managing internet and computer resources, cataloged their current system configurations, and installed the study computer and telemedicine counseling equipment, which facilities will keep as partial reimbursement for participating in the trial. He tested the telemedicine counseling connection, trained site staff on its use, and placed connection checklists, troubleshooting tips, and phone numbers to call in telemedicine counseling examining rooms. The technician met with internet service managers at each site and became familiar with site firewall configurations to facilitate installation and troubleshooting during counseling sessions. This was necessary as a pilot study revealed that some sites would require the creation of a port to allow high-bandwidth signals to get through clinic and internet service provider firewalls. These high quality video signals are transmitted interactively between sites using the Polycom PVX personal video conferencing system, in order to provide high quality videoconferencing from the study desktop personal computers. Polycom PVX integrates a standard web camera with the study desktop computers and clinics' existing high-speed internet service. Port issues exist for only a subset of facilities as many internet providers are designing firewalls to accommodate video in response to clinic demand.

2.4. Participants

Participants were recruited through 20 primary care practices and safety net clinics in Kansas. Practice-based recruitment included direct referral of smokers via participating physicians, recruitment via medical students who were in the clinics for rural clinical preceptorships, and chart review. The chart reviews were conducted by clinic or study staff depending on the preference of the clinic. Reviews sought to identify all smokers, 18 years or older, who had been seen in clinics in the past 3 years. Study or clinic staff mailed invitations to all clinic smokers, printed on clinic letterhead, that endorsed the study, described the procedures, and notified smokers that study staff would contact patients by phone to screen for interest and eligibility. The letter included instructions for how patients could opt out from contact with study staff by calling a toll-free number. Research staff telephoned patients who had not opted out one week after the mailing to screen, verify eligibility, collect consent, and baseline data. The Project Manager randomized patients to either arm by opening concealed envelopes which contained the randomization. Counselors called participants one week after enrollment and informed participants of their randomization.

In addition, community-based recruitment efforts were conducted primarily in western Kansas to recruit Latino smokers. Latino recruitment included on-site recruitment by study staff, word of mouth, participant referrals, radio advertising, health

---

2. Measures and reimbursement.

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline</th>
<th>Month 3</th>
<th>Month 6</th>
<th>Month 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics, smoking history, medication access</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-reported smoking endpointsa</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Potential mediatorsb</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Potential moderatork</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary cotinine and proxy verificationd</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

Provider/participant costs Collect at end of study

Satisfaction, feasibility among patients

Satisfaction, feasibility among practices

For patients $20 $20 $20 $50

---

a Includes self-reported 7-day abstinence, 30-day abstinence, number of cigarettes per day.
b Includes measures of autonomy supportiveness, autonomous motivation, perceived competence, therapeutic alliance, medication use, frequency/quality of physician counseling, counseling adherence.

c Includes measures of depression (PHQ-2), alcohol (AUDIT-C), anxiety (GAD-2), health comorbidities, use/access to computers.
d Salivary cotinine will be collected at baseline and 12 months, but not analyzed at baseline.
fairs, newsletters, press releases, and recruitment tables at Latino worksites, religious organizations, and businesses.

Eligible smokers were required to have a primary care physician who was participating in the study, be 18 years of age or older, smoke 5 or more cigarettes per day for at least one year, smoke 25 out of the past 30 days, speak English or Spanish, and have a telephone. Individuals were excluded if they used other tobacco products, were currently taking quitting smoking medications or participating in another quit smoking program, were breast feeding, pregnant or planning to become pregnant, planning on moving in the next year, did not have a health care provider they regularly saw at the clinic, or lived with a smoker already enrolled in the study.

2.5. Intervention and control components

Table 1 depicts the study components. Within the first week after enrollment, all study participants received a study welcome packet via mail. The welcome packets included printed educational materials on smoking cessation, a time line of the intervention, and a pharmacotherapy guidance form. Approximately one week after the packet was mailed, counselors called participants to notify them of their group assignment and to schedule their first counseling session.

2.5.1. Counseling format

Patients in ITM received 4 sessions of clinic-based video telemedicine counseling for smoking cessation. The counseling approach was based on Combined Behavioral Intervention (CBI), a combination of Motivational Interviewing and Cognitive Behavior Therapy [18-20]. Because most computers were located in rooms set aside for telemedicine smoking cessation during designated hours, participants could sign in at the reception and be taken directly to the room for their session. Clinic staff, either a receptionist or a nurse, called the counselor at the medical center to initiate the session. At the end of each session, counselors directed participants to go to the clinic receptionist to schedule the next session. Counselors then telephoned the receptionist while the participant was at the front desk to coordinate scheduling the next appointment. The telephone condition (Phone) was designed to mimic tobacco quitline counseling and consisted of 4 sessions delivered via telephone. At the end of each session, counselors scheduled the next counseling session with the patient.

2.5.2. Pharmacotherapy guidance

At baseline, study staff collected information on insurance coverage, income, prescription medication use, and pre-existing health conditions that are contraindications or cautions for cessation medications. Counselors used this information to complete a “pharmacotherapy guidance form” to help all patients identify what medications were safe for them, understand what resources they had to pay for medications, and facilitate a planning process for the patient to select and obtain medications. This form was completed based on information collected from study participants at baseline. The form was provided to participants in a personalized, pre-filled-out manner in their mailed ‘welcome packet.’ Income-eligible patients with no insurance coverage are eligible for pharmacy assistance programs (PAPs) offered through pharmaceutical drug companies. Pharmacotherapy guidance materials and quit plans were transmitted via fax to the clinic office in the ITM condition and via mail to the patients’ homes in the Phone condition.

2.5.3. Counseling content

The goals of session 1 (week 0) were to elicit, acknowledge, and reinforce the client’s motivation to change, learn lessons from past quit attempts, review the pharmacotherapy guidance form, explore patients’ thoughts and feelings about pharmacotherapy, and invite the patient to develop their personal quit plan. Patient’s not ready to quit were encouraged to set goals such as cutting down, establishing home smoking restrictions, and were encouraged to explore their ambivalence for quitting smoking. For all participants, after each session counselors either mailed (Phone) or faxed (ITM) two copies of the most recent version of the patient’s quit plan which for some patient’s included information to the PCP that the patient was not ready to quit and two copies of the pharmacotherapy guidance form. Counselors encouraged patients to provide materials to medical staff for inclusion in the medical record and to consult with their physician on questions and scripts for prescription medications.

In subsequent sessions (sessions 2–4 at weeks 1, 4, and 8), counselors invited patients to choose the topic of each session. Participants had 12 topics to choose from. Among participants who had quit, sessions addressed thoughts and behaviors that created challenges to remaining abstinent. Among patients who had slipped or relapsed, sessions focused on rebuilding motivation and confidence, learning from slips, and making new quit plans.

2.5.4. Fidelity assessment

To ensure fidelity to the counseling protocol all counselors participated in weekly supervision led by PhD-level experts in smoking cessation. During supervision sessions digital audio files were reviewed and rated using an adapted version of the fidelity monitoring forms we have used successfully in prior studies [21-23]. To assess whether counseling was the same across ITM and Phone sessions we obtained independent ratings of counselor adherence on a randomly selected subset of sessions. These audio files were encrypted, blinded regarding group assignment, and emailed to an independent expert rater for coding on a monthly basis. At the end of the trial, these scores will be collapsed into a summative assessment of counseling fidelity for each study arm.

2.5.5. Assessment schedule and reimbursement (Table 2)

Clinics that participated in the study received a $1000 reimbursement for incidental costs associated with the trial; $500 at enrollment and $500 at the end of the study. In addition, intervention sites received a computer and individually licensed Polycom PVX software for implementing the intervention. Clinics dedicated the equipment to the telemedicine trial for the duration of the study but kept the equipment at the end of the trial. Participants received twenty dollar shopping vouchers for completing study assessments at 0, 3, and 6 months. At twelve months participants received a fifty dollar voucher for completing the final study assessment. In addition, participants who self reported that they quit at 12 months and provided a salivary sample received an additional fifty dollar shopping voucher. Participants are not informed of...
the $50 additional incentive for mailing in their saliva sample until after they self-reported their abstinence and completed the entire 12 month questionnaire in order to reduce participant incentive to misreport smoking status.

2.6. Measures

2.6.1. Baseline measures

General demographic variables such as age, gender, marital status, education, employment status, income, race and ethnicity were collected (Table 3). Smoking history included number of cigarettes per day, quitting history, previous quit smoking medications, and age of initiation. Nicotine dependence was assessed with the six-item Fagerström Test for Nicotine Dependence (FTND) scale [24]. Readiness to quit was measured using the Stages of Change 4-item questionnaire [25]. Motivation and confidence to quit smoking were measured using 10 point Likert scales with higher scores indicating greater motivation/confidence.

2.6.2. Study endpoints—cessation and verification

The primary outcome measure was 7-day point prevalence smoking abstinence at 12 months after enrollment (i.e. ‘having smoked no cigarettes, not even a puff in the past 7 days’) [26]. Month 12 abstinence was verified via mailed salivary cotinine analysis, with a cut point of 15 ng/ml [27]. We also conducted validation via proxy report from a significant other among quitters who did not return a salivary sample [28].

Secondary outcomes at 3, 6, and 12 months included self-reported point prevalence abstinence; frequency and duration of quit attempts; average number of cigarettes smoked per day; and prolonged abstinence. Prolonged abstinence as defined in this study included a “grace period” of 1-month at the beginning of treatment to allow the treatment to take effect (i.e. ‘one month after the first counseling session, having smoked no cigarettes in the past 2 consecutive weeks, including weekends’) [26].

2.6.3. Mediators

Potential mediators were assessed at 3, 6 and 12 months. Participants responded to the 6-item Health Care Climate Questionnaire (HCCQ) [29] to assess their perceptions of the degree to which their health care providers are autonomy-supportive in discussing smoking cessation. Participants' autonomous motivation was assessed with the 12-item Treatment Self-Regulation Questionnaire (TSRQ) [29]. Patients’ perceptions of competence for smoking cessation were measured using the 4-item Perceived Competence Scale for Cessation (PCSC) [30].

In addition data were collected on adherence to counseling sessions. Adherence to pharmacotherapy was collected via self-report, which included the type, frequency, and duration of medications used.

2.6.4. Moderators

The two-item Patient Health Questionnaire (PHQ-2) [31] was used to measure depression with scores of 3 or higher indicating clinical depression. The two-item General Anxiety Disorder questionnaire (GAD-2) assessed anxiety with scores of 3 or higher indicating anxiety [32]. In addition, the study screening form included 3 alcohol consumption questions from the Alcohol Use Disorders Identification Test (AUDIT-C) as a brief screening test for heavy drinking and/or active alcohol abuse or dependence with a cutoff score of greater than four for males and greater than three for females [33]. Patients reported how many times they had seen their regular doctor in the past 12 months, and whether any health care provider ever told them that they had diabetes, hypertension, hyperlipidemia, stroke, chronic lung disease, heart disease, cancer, or depression.

2.6.5. Computer use and availability

Participants were also asked four questions related to their perceptions of using computer technology such as telemedicine for the delivery of health care. In addition, computer and internet availability within the home were assessed.
2.6.6. Cost effectiveness

The purpose of our cost effectiveness analysis was to examine the differential impact and the relative cost per quit of ITM versus Phone. Program variable costs included counselor time, phone charges, and written materials. Fixed costs included personnel costs incurred in administration or oversight of the program (program director and support staff), facility costs (rent, maintenance, utilities, internet access charges), office supplies, and equipment (computers, web cams, printers, telephones).

2.7. Analyses for Connect2Quit baseline characteristics (present study)

In the present study, we report demographic characteristics, computer/internet access, attitudes related to telehealthcare, and other moderator variables that were collected during the baseline assessment. We also summarize participants' smoking history and patterns of smoking and dependence. Categorical variables are summarized by frequencies and percentages, and quantitative variables are summarized by means and standard deviations.

2.8. Statistical and power analyses for Connect2Quit outcomes (future outcome studies)

Below, we briefly outline our sample size analyses and other analyses that we will conduct when the study is complete.

2.8.1. Sample size and power

The primary endpoint is cotinine verified 7-day point prevalence abstinence at 12 months. We expect an 8% cessation rate in the Phone arm. Studies employing in-home telephone counseling among persons who were recruited from primary care practices have reported unverified quit rates ranging from 11–12% [34]. With a primary endpoint of verified abstinence we anticipate a slightly lower (8%) abistent rate in the Phone arm compared to these unverified studies. A 16% cessation rate is expected in the ITM arm based upon a meta-analysis of 45 studies found that 4–8 person-to-person treatment sessions yields a long-term abstinence rate of 18%–24% [16]. Telemedicine has been shown repeatedly to perform as well as face-to-face office visits across a number of health outcomes, we anticipate lower quit rate as ITM will be conducted at a distance without direct counselor and clinical staff interactions post session. We implement a process recommended by Muthén and Muthén [35] to examine sufficient sample size for our structural equation modeling (SEM) analyses. Using Mplus 5 software, [36] this method took into account the expected nonindependence of observations due to cluster sampling, using Monte Carlo simulations to examine model fit and prediction of cessation by major variables of interest. Our sample size of 283 per group is more than adequate for the SEM analyses.

2.8.2. Hypothesis testing

The primary analysis for Hypothesis 1 will be a comparison of ITM versus Phone 12-month, 7-day point prevalence verified abstinence rates using a chi-square test. Using the intent to treat principle, subjects lost to follow-up and those who claim to be abstinent but who fail to submit a salivary cotinine sample, will be coded as smokers. A multivariable logistic regression with being smoking status as the dependent variable will be used to adjust for covariates that might affect cessation, such as age, gender, income, and education level. The logistic regression model will include a main effect term for group.

A main focus of our analyses will be to assess how our intervention had an impact on outcome. To do so, we will use structural equation modeling (SEM), with robust maximum likelihood estimation and standard errors adjusted for clustering by clinic site, to determine how well ITM operationalizes key features of the intervention and which components of the intervention are important for smoking cessation.

3. Results

3.1. Recruitment

Of 2418 individuals who were offered assessment for eligibility, 828 declined to be screened, 874 did not meet eligibility criteria, 716 were eligible and 566 were respectively randomly assigned to either ITM or Phone (see Fig. 1). Reasons for ineligibility (not shown) included no longer being a smoker (18/874, 55%), did not have a regular health care provider at the clinic (85/874, 9.7%), and smoked fewer than 5 cigarettes per day (72, 8.2%), moved or is planning to move (44, 5%), pregnant or breastfeeding (44, 5%), other (used other forms of tobacco, had another household member in the trial, etc.) (104, 12%). Participants enrolled per clinic varied widely from 2 participants in one clinic to 150 participants in another with an average enrollment of 28.3 participants per clinic.

3.2. Participant demographics

Mean age of study participants was 47.5, and 65% of participants were female. Nearly 9% were Hispanic/Latino. Nearly 1 in 5 had less than a high school education. Well over half of our samples were living at less than 200% of the Federal Poverty Level, 63.1% had health insurance; of these, only 57.1% had insurance that covered any form of cessation medication. Most of the sample had some form of medical comorbidity, including overweight and/or obesity. Many of our participants experienced some form of mental health comorbidity, with nearly half experiencing depressive symptomology.

3.3. Telemedicine variables

Although most (nearly 70%) had a working computer at home, one out of three lacked home internet access, 40% were not comfortable using computers, and only 4% had been seen by a doctor via telemedicine in the past (Table 4). Many were not confident that personal information was kept private via technology, were not comfortable using newer communication technologies, and were not interested in receiving telecare at home.

3.4. Tobacco use

Table 5 displays tobacco use history and interest in quitting. Participants smoked on average a pack of cigarettes per day, and at a group mean of 4.9 on the FTND, had moderate nicotine dependence. They smoked on average 17 years, and most had...
tried some form of quit smoking medication in the past to quit. They were highly motivated to quit, with most in "preparation" to quit and on average felt it was highly important (9.4) for them to quit.

4. Discussion

Connect2Quit is the first RCT examining telemedicine for the treatment of tobacco dependence, which is the top preventable cause of death in the United States. We were able to recruit a full complement of clinics and participants into the trial, which suggests that both practitioners and patients are able and willing to participate in video counseling-delivered tobacco treatment in rural areas.

Our participant sample was diverse and included low-income smokers with comorbidities known to be prevalent in rural areas. Many clinical trials exclude high-risk participants and test interventions on highly select populations. Our study pool has representation from a wide variety of smokers, recruited from 20 different primary care practices and safety net clinics. Because we recruited through safety net clinics as well as private primary care practices, many of our participants lacked health insurance and coverage for cessation medications. Hence, our study will be a representative of the majority of smokers in rural areas, who have health and mental health comorbidities and who lack access to insurance and cessation medications. Moreover, data on computer and technology use suggest ITM may be a good fit for participants, who could have difficulty accessing or navigating a computer-based intervention in their homes.

Similar to past studies, our participants have high rates of depression; we also found they experience significant anxiety. The GAD-2 is a very brief screening tool that indicates the likely presence of an anxiety disorder. There is strong evidence of a link between smoking and mental health, including anxiety disorders, [37] and the prevalence observed in this study of 40% is around double that reported in primary care and population-based surveys [32,38].

We designed Connect2Quit to be simple, translatable, and sustainable to enhance its potential for widespread adoption and ultimate impact on public health. The accounting cost analysis will provide useful information about the actual costs of implementing ITM in real world clinical practices. The potential health impact is large because the prevalence of smoking is high in rural areas, access to smoking cessation services is low, Medicare reimbursement creates a strong potential for widespread adoption, and the economic benefits (cost-benefits) of smoking cessation are considerable. Should ITM prove effective, it will have strong potential for improving access to high-quality tobacco treatment in rural areas.

<table>
<thead>
<tr>
<th>Computer, internet, and telemedicine use</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Currently have a functional computer at home¹, n (%)</td>
<td>395 (69.9)</td>
</tr>
<tr>
<td>Currently have internet access at home¹, n (%)</td>
<td>379 (67.1)</td>
</tr>
<tr>
<td>Ever been seen by a doctor via telemedicine, ITV or webcam¹, n (%)</td>
<td>25 (4.4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attitudes toward computers, communication technology, and health technology</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I am comfortable using computers¹, n (% agree–strongly agree)</td>
<td>339 (60)</td>
</tr>
<tr>
<td>I am comfortable using other communication technologies, such as mobile phones, mp3 players, or web cameras¹, n (% agree–strongly agree)</td>
<td>355 (62.8)</td>
</tr>
<tr>
<td>I am interested in receiving health care in my home using computers or communication technologies², n (% agree–strongly agree)</td>
<td>326 (57.7)</td>
</tr>
<tr>
<td>I am confident my personal information is kept private when using communication technologies¹, n (% agree–strongly agree)</td>
<td>381 (67.4)</td>
</tr>
</tbody>
</table>

¹ N = 565.
Table 5

Smoking patterns and history.

<table>
<thead>
<tr>
<th>Smoking pattern</th>
<th>Current smoking</th>
<th>Current cigarettes per day&lt;sup&gt;a&lt;/sup&gt;, mean (SD)</th>
<th>Fagerström Test for Nicotine Dependence (FTND)&lt;sup&gt;a&lt;/sup&gt;, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of quit attempts in the past 12 months&lt;sup&gt;a&lt;/sup&gt;, mean (SD)</td>
<td>17.1 (5.0)</td>
<td>4.9 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Prior use of pharmacotherapy&lt;sup&gt;b&lt;/sup&gt;, n (%)</td>
<td>287 (50.8)</td>
<td>187 (33.1)</td>
<td></td>
</tr>
<tr>
<td>Nicotine replacement patch</td>
<td>61 (10.8)</td>
<td>16 (9.4)</td>
<td></td>
</tr>
<tr>
<td>Nicotine gum</td>
<td>163 (28.9)</td>
<td>166 (29.4)</td>
<td></td>
</tr>
<tr>
<td>Nicotine lozenge</td>
<td>393.9 (923.4)</td>
<td>9 (1.5)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> N = 566.  
<sup>b</sup> N = 566.  
<sup>c</sup> N = 566.

Interest in quitting

<table>
<thead>
<tr>
<th>Readiness to stop smoking&lt;sup&gt;c&lt;/sup&gt;, n (%)</th>
<th>Precontemplation</th>
<th>Contemplation</th>
<th>Preparation</th>
<th>Importance of quitting [0 (low)–10 (high)]&lt;sup&gt;c&lt;/sup&gt;, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparation</td>
<td>15 (2.7)</td>
<td>221 (39.1)</td>
<td>329 (58.2)</td>
<td>9.4 (1.5)</td>
</tr>
</tbody>
</table>

Acknowledgments

The project described was supported by Award Number RO1HL087643 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

Author contributions

LM completed the first draft of this manuscript and served as project director for the first year of the project. EF contributed to the study design and assisted in recruitment of clinics. APC helped design the SEM model and oversaw all aspects of telemedicine implementation. DC and LL helped design the SEM model and oversaw all aspects of Spanish translation.

References


Muthén LK, Muthén BO. How to use a Monte Carlo study to decide on sample size and determine power. Los Angeles, CA: Muthén & Muthén; 2002.

